An Open Label Study to Assess the Efficacy, Safety and Tolerability of COZAAR Plus (Losartan Potassium 50mg/Hydrochlorothiazide 12.5mg) Possibly Titrated up to COZAAR Plus-F (Losartan Potassium 100mg/Hydrochlorothiazide 25mg) in Patients With Essential Hypertension (0954A-325)

Organon

Status and phase: Terminated; Phase 3

Conditions: Hypertension

Treatments: Drug: MK0954, losartan potassium / Duration of Treatment - 12 weeks

Study type: Interventional

Funder types: Industry

Identifiers

NCT00449111

0954A-325

2007_005

Details and patient eligibility

About

Evaluate blood pressure after 6 weeks of treatment with COZAAR plus.

Enrollment: 11 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient treated with valsartan 80mg or irbesartan 150mg or vandesartan 8mg for at least 4 weeks prior to visit 1
• Patient with systolic blood pressure between 140 to 159 mmhg and diastolic pressure between 90 to 99mmhg taken at visit 1

Exclusion criteria

• History of angina pectoris that has not been stabilized in the past 6 weeks
• History of clinically significant abnormal lab results or diseases
• Myocardial infarction within the past 6 months
• Stroke in the past 6 months

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)